Literature DB >> 30954968

Risk of severe herpes simplex virus infection in systemic lupus erythematosus: analysis of epidemiology and risk factors analysis in Taiwan.

Tzu-Hao Li1,2,3, Chien-Chih Lai2,3,4, Wen-Hsiu Wang5,6, Wei-Sheng Chen4, Yen-Po Tsao4, Chang-Youh Tsai2,4, Yu-Sheng Chang7,8,9.   

Abstract

OBJECTIVE: Patients with systemic lupus erythematosus (SLE) are susceptible to herpes simplex virus (HSV) infection, which occasionally leads to severe complications including meningoencephalitis and keratitis. However, few attempts to analyse the associated incidence and risk factors have been made.
METHODS: We enrolled patients with SLE recorded between 1997 and 2012 and compared the incidence rate (IR) of severe HSV infection, including meningoencephalitis, septicaemia, ocular and visceral involvement, and other specific complications demanding hospitalisation, with that of a non-SLE cohort. A Cox multivariate proportional hazards model was applied to analyse the risk factors of severe HSV infection in patients with SLE.
RESULTS: A total of 122 520 subjects (24 504 patients with SLE and 98 016 age-matched and sex-matched non-SLE controls) were included, and a higher IR of severe HSV infection was revealed in the SLE group (IR ratio=3.93, p<0.001). In patients with SLE, previous oral and genital infection (HR=2.29, p=0.049), intravenous steroid pulse therapy (HR=5.32, p<0.001) and daily oral dose of over 7.5 mg of prednisolone (HR=1.59, p=0.024) were independent risk factors for severe HSV infection, whereas age of ≤18 (HR=0.45, p=0.029) was a protective factor.
CONCLUSIONS: Patients with SLE are at higher risk of severe HSV infection, and related risk factors include being older than 18 years, having a history of HSV mucocutaneous infection, recent receipt of steroid pulse therapy and a daily oral dose of steroid over 7.5 mg prednisolone. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  herpes simplex virus; keratitis; meningoencephalitis; systemic lupus erythematosus

Year:  2019        PMID: 30954968     DOI: 10.1136/annrheumdis-2018-214844

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  5 in total

1.  Understanding COVID-19 Risk in Patients With Immune-Mediated Inflammatory Diseases: A Population-Based Analysis of SARS-CoV-2 Testing.

Authors:  Lihi Eder; Ruth Croxford; Aaron M Drucker; Arielle Mendel; Bindee Kuriya; Zahi Touma; Sindhu R Johnson; Richard Cook; Sasha Bernatsky; Nigil Haroon; Jessica Widdifield
Journal:  Arthritis Care Res (Hoboken)       Date:  2021-09-06       Impact factor: 5.178

2.  Autoimmune Diseases and COVID-19 as Risk Factors for Poor Outcomes: Data on 13,940 Hospitalized Patients from the Spanish Nationwide SEMI-COVID-19 Registry.

Authors:  María Del Mar Ayala Gutiérrez; Manuel Rubio-Rivas; Carlos Romero Gómez; Abelardo Montero Sáez; Iván Pérez de Pedro; Narcís Homs; Blanca Ayuso García; Carmen Cuenca Carvajal; Francisco Arnalich Fernández; José Luis Beato Pérez; Juan Antonio Vargas Núñez; Laura Letona Giménez; Carmen Suárez Fernández; Manuel Méndez Bailón; Carlota Tuñón de Almeida; Julio González Moraleja; Mayte de Guzmán García-Monge; Cristina Helguera Amezua; María Del Pilar Fidalgo Montero; Vicente Giner Galvañ; Ricardo Gil Sánchez; Jorge Collado Sáenz; Ramon Boixeda; José Manuel Ramos Rincón; Ricardo Gómez Huelgas
Journal:  J Clin Med       Date:  2021-04-23       Impact factor: 4.241

3.  Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection.

Authors:  António Ferreira; António Oliveira-E-Silva; Paulo Bettencourt
Journal:  J Med Virol       Date:  2020-07-27       Impact factor: 20.693

4.  The correlation between SARS-CoV-2 infection and rheumatic disease.

Authors:  Zhao-Wei Gao; Xi Wang; Fang Lin; Ke Dong
Journal:  Autoimmun Rev       Date:  2020-05-01       Impact factor: 9.754

Review 5.  On the genetics and immunopathogenesis of COVID-19.

Authors:  Chaim Oscar Jacob
Journal:  Clin Immunol       Date:  2020-09-10       Impact factor: 3.969

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.